Breast, Ovarian and Uterine Cancer

Breast, Ovarian and Uterine Cancer

The most common of all cancers to affect women is breast cancer, with as many as one-in-eight women contracting it during their lifetime. Approximately 10% of all breast cancer cases are due to DNA mutation(s), while risk for breast cancer can be further augmented by factors such as age, lifestyle choices, reproductive history and more.

Hereditary mutations in certain genes, such as BRCA1 and BRCA2, commonly result in the early-onset of breast cancer, recurrent breast cancer and breast cancer involving both breasts. Genes that are associated with breast cancer can often also cause ovarian cancer.

Breast, Ovarian, and Uterine Cancer Gene Testing (Gx™ BrOvUtCa)

Gx™ BrOvUtCa is a comprehensive hereditary breast and ovarian cancer risk assessment include germline sequencing of 26 genes

 ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDKn2A, CHEK2, DICER1, EPCAM, MLH1, MRE11A, MSH2, MSH3, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53

Gx™ BrOvUtCa can identify the specific risk or cause factor for breast cancer, ovarian and uterine cancers. Identification of a specific genetic mutation provides important information for a better care in at least the following conditions:

• Two primary breast cancers or clustering of breast and ovarian cancer, and uterine cancer.
• Early-onset breast cancer (<50 years-of-age) or bilateral breast cancer.
• Presence of male breast cancer.
• Ovarian cancer at any age.

Option to test for a more extended Gx™ InhCa Gene Testing is available